… cell cycling or transcription factors. Factors for which there is now substantial clinical evidence
of a link to small cell lung cancer (… In non-small cell lung cancer (NSCLC), the strongest …

… Conventional cytotoxic chemotherapy (CCC) is the backbone of non-small-cell lung cancer
(NSCLC) treatment since decades and still represents a key element of the therapeutic …

… In this Review, we describe the available data on clinical efficacy, the emerging evidence
regarding biomarkers and ongoing clinical trials using ICIs and other immunotherapies in …

… Purpose: The aim of this study was to evaluate the efficacy and toxicity of gemcitabine at
higher doses than had been used previously in patients with non-smallcell lung cancer (NSCLC)…

… Lung stereotactic body radiotherapy (SBRT) is considered a standard curative treatment
for medically inoperable early stage non–small-cell lung cancer (… objective of the study is to …

… advanced non-small cell lung cancer. Here, we report safety and efficacy data from a
large, global, open-label, phase IV trial of erlotinib (Tarceva Lung Cancer Survival Treatment). …

… time from mitotic arrest to cell death and therefore may increase the window of time when
taxanes are efficacious. We also show that non–small cell lung cancer (NSCLC) models with …

… -cell lung cancer (NSCLC) is based on clinical trials experience. Molecular characteristics that
impact metabolism and efficacy … determinant of gemcitabine efficacy. Excision repair cross-…

… the efficacy of tumor vaccination and … Lung cancer is the leading cause of cancer-related
mortality worldwide. Non–small-cell lung cancer (NSCLC) comprises 85% of all lung cancers …

… in this study. Second primary cancers are common in patients with lung cancer and are
associated with similar carcinogenic exposure throughout the lung field (34). Although it is …